# Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma

> **NCT00074178** · PHASE2 · COMPLETED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 22 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** pegfilgrastim
- **DRUG:** cyclophosphamide
- **DRUG:** cytarabine
- **DRUG:** dexamethasone
- **DRUG:** etoposide phosphate
- **DRUG:** methotrexate

## Key facts

- **NCT ID:** NCT00074178
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-01
- **Primary completion:** 2006-07
- **Final completion:** 2006-07
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2017-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00074178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00074178, "Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00074178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*